Silence Therapeutics Plc (SLN.L) said it has signed an agreement with MiReven Pty Ltd. to assess the delivery potential of Silence Therapeutics' proprietary delivery systems with MiReven's novel microRNA-based therapeutics. MiReven, an Australian-based microRNA company, is commercialising discoveries from the Western Australian Institute for Medical Research on the anti-cancer potential of miR-7.
As per the terms of the agreement, Silence Therapeutics will formulate a miR-7 mimetic with its proprietary AtuPLEX, DACC and DBTC delivery systems in order to assess miR-7 in various cancer models. The company will undertake in vitro and in vivo studies of the formulated miR-7. Silence Therapeutics is being paid an undisclosed fee for the collaboration.
Click here to receive FREE breaking news email alerts for Silence Therapeutics and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com